All In Biotech

Drug Trial Radar · NCT04025541

Analysis of Circulating Tumor Markers in Blood

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

992

Planned (sponsor's estimate)

Start

May 29, 2018

Primary completion

May 29, 2029

Study completion May 29, 2032

Sponsor

Lead sponsor
Institut du Cancer de Montpellier - Val d'AurelleAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.

Conditions

  • Cancer
  • Breast Cancer
  • Sarcoma
  • Lung Cancers
  • Glioma
  • Colon Cancer

Interventions

  • Blood samplingBiological

    blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time

  • Blood sampling C3Biological

    Blood samples will be collected at four key time points: * baseline (T1), * first scan assessment (T2), * second scan assessment (T3), * and progression (T4).

  • Blood sampling C4/7/10/13Biological

    Blood samples will be collected before any treatment

  • Blood sampling C5Biological

    Blood samples will be collected at four key time points: * At the inclusion (T1) * Before the beginning of the treatment (cycle 1 day 1) (T2) * After the first cycle of T-DXd (cycle 2 day 1) (T3) * At progression or at the end of the follow-up (after 3 years) (T4)

  • Blood sampling C6Biological

    Blood samples will be collected at three key time points: * At the inclusion (T1) * For patients starting treatment at the time of inclusion (T2): * Chemotherapy: 3 months after inclusion, * Concurrent chemoradiotherapy with Temozolomide: 4-6 weeks after completion of radiotherapy, * For patients starting treatment at the time of inclusion: at the time of tumor progression if occurring within one year of inclusion, or 12 months after inclusion in the absence of progression (T3).

  • Blood sampling C8Biological

    Blood samples will be collected at five key time points: * At the inclusion * At follow-up visit 2 to 6, every 3 months

  • Blood sampling C9Biological

    Blood samples will be collected at four key time points: * At the inclusion before the beginning of the treatment (Cycle 1 Day 1) * After the first cycle of the first chemo-immunotherapy sequence (Cycle 2 Day 1) * After the first cycle of the second chemotherapy sequence (Cycle 2b Day 1) * After the end of the whole neo-adjuvant chemo-immunotherapy protocol, before surgery

  • Blood sampling C11 + FFPEBiological

    Blood samples will be collected at five key time points: * At the inclusion (T1) * At first clinical evaluation (T2): 4th week after start of treatment * At first scan evaluation (T3a): 8th week after start of treatment * At the Nth scan evaluation (T3b, c, ...) * At progression (T4) Tumor sampling : * At the inclusion * At tumor progression

  • Blood sampling C12Biological

    Blood samples will be collected at several points : * Inclusion: at the time of suspected leptomeningeal metastases, prior to any specific treatment, * Every 4 weeks until meningeal progression, or for a maximum of 4 months, * Then every 3 months beyond 4 months until meningeal progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimation of the feasibility of the various blood tumoral biomarkers analysisTime frame: 4 YEARS

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle

    Montpellier, France · Recruiting

  • ICM

    Montpellier, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.